Abstract: Objective To analyze the clinical significance and economic analysis of RhD, C, c, E, e antigen compatible blood transfusion in our hospital, and provide scientific basis for the comprehensive promotion and popularization of Rh compatible blood transfusion and the decision-making of health administrative departments in the future. Methods We screened and identified the production of unexpected antibodies between Rh compatible transfusion group and control group. The length of hospital stay (LOS) and the cost of transfusion-related testing were analyzed in the two years before and after Rh phenotyping. Results The Rh antigen compatibility between donors' red blood cells and patients was high enough to transfuse Rh matched red blood cells for 92.43% of patients. The total ratio of unexpected antibodies was 1.72% (186/10,786), the antibody frequency of Rh system was 43.30%, anti-Mi^a was 20.98%. There is no new development of Rh system antibodies after Rh compatible transfusion. After Rh phenotyping, the mean LOS and the cost of red blood cells were slightly decreased. Conclusion Rh compatible transfusion can significantly diminish new unexpected antibodies. The increased cost of transfusion-related testing due to Rh compatible transfusion did not significantly increase medical costs. Rh compatible blood transfusion is worth promoting and popularizing.

Key words: Rh compatible transfusion, Unexpected antibody, Cost